To investigate this further, we used T cell receptor α (TCRα) knockout mice, which are deficient in CD4+ and CD8+ αβ T cells, and treated tumor-bearing mice with GSK2879552 as aforementioned. This evidence concerns the gene CD4 and neoplasm.